Open AccessModality switching between therapy and imaging based on the excitation wavelength dependence of dual-function agents in folic acid-conjugated graphene oxides
Author(s) -
Seung Won Jun,
Jun-Young Kwon,
Soo Kyung Chun,
Hyun Ah Lee,
Jaebeom Lee,
Dae Youn Hwang,
Chongying Dong,
Chang-Seok Kim
Publication year - 2018
Publication title -
biomedical optics express
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.362
H-Index - 86
ISSN - 2156-7085
DOI - 10.1364/boe.9.000705
Subject(s) - graphene , photothermal therapy , materials science , laser , femtosecond , optoelectronics , wavelength , optics , nanotechnology , physics
Owing to its near infrared (NIR) absorption, graphene oxide (GO) is promising for both photothermal (PT) therapy and multiphoton (MP) imaging. Novel therapy/imaging modality switching is proposed here based on the selected excitation wavelength of femtosecond (FS) laser. GO-based destruction of cancer cells is demonstrated when the laser power of 800-nm-wavelength FS laser is increased above 7 mW. However, GO-based imaging is mainly monitored without damaging the sample when using 1200-nm wavelength FS laser in the same laser power range. Folic acid (FA) conjugated graphene oxide (FA-GO) was synthesized for selective cancer cell targeting. Dual-function FA-GO-based cancer cell targeting agents were experimentally optimized to enable therapy/imaging modality switching.